Evidence map›Paper›PMID 40643789›Full record

ArticleCurrent microbiology2025

Molecular Characterization and Antibiograms of Nontuberculous Mycobacterium Infections in Kashgar, China.

Yiting Wang, Huiwen Zheng, Xijiang Wang, Xinqi Wang, Nianqiang Liu, Le Wang, Zhenjiang Liu, Xiangli Meng, Maiweilanjiang Abullimiti, Maimaitiaili Aihemuti and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CutaneousMicroorganisms · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yiting Wang *National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Huiwen ZhengLaboratory of Respiratory Diseases, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Center for Children's Health, Beijing, 100045, China.
Xijiang WangCenter for Tuberculosis and Leprosy Prevention and Control, The Center for Disease Control and Prevention of Xinjiang Uygur Autonomous Region, UrumqiXinjiang, 830026, China.
Xinqi WangCenter for Tuberculosis and Leprosy Prevention and Control, The Center for Disease Control and Prevention of Xinjiang Uygur Autonomous Region, UrumqiXinjiang, 830026, China.
Nianqiang LiuCenter for Tuberculosis and Leprosy Prevention and Control, The Center for Disease Control and Prevention of Xinjiang Uygur Autonomous Region, UrumqiXinjiang, 830026, China.
Le WangCenter for Tuberculosis and Leprosy Prevention and Control, The Center for Disease Control and Prevention of Xinjiang Uygur Autonomous Region, UrumqiXinjiang, 830026, China.
Zhenjiang LiuTuberculosis Dispensary of Kashgar Prefecture, Kashgar, 844099, Xinjiang, China.
Xiangli MengNingbo International Travel Healthcare Center, Ningbo Customs District P.R. China, Ningbo, 315012, China.
Maiweilanjiang AbullimitiTuberculosis Dispensary of Kashgar Prefecture, Kashgar, 844099, Xinjiang, China.
Maimaitiaili AihemutiTuberculosis Dispensary of Kashgar Prefecture, Kashgar, 844099, Xinjiang, China.
Fang HuangInstitute for Immunization and Prevention, Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing, 100017, China.
Fei HuangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Xichao OuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. ouxc@chinacdc.cn.
Senlu WangCenter for Tuberculosis and Leprosy Prevention and Control, The Center for Disease Control and Prevention of Xinjiang Uygur Autonomous Region, UrumqiXinjiang, 830026, China.
Yanlin ZhaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. zhaoyl@chinacdc.cn.

Funding

Applied Technology Research and Development Programing Project of Kashgar Prefecture 231 KS2021034Applied Technology Research and Development Programing Project of Kashgar Prefecture KS2021031China CDC-Tuberculosis Control and Prevention Project 2528Key Technologies Research and Development Program 2022YFC2305200Natural Science Foundation of Beijing Municipality 7224328Natural Science Foundation of Ningbo Municipality 2018A610238)Natural Science Foundation of Xinjiang 2021A01D145Natural Science Foundation of Xinjiang 2022D01A115
6 · The paper itself

Abstract

To investigate the prevalent characteristic of nontuberculous mycobacteria (NTM) isolates in Kashgar. A total of 52 NTM culture-positive isolates were collected in 2020 from Kashgar, China. All strains were confirmed to be NTM species by whole genome sequencing (WGS). Drug susceptibility testing was performed using Sensititre SLOMYCO plates. Of the 52 NTM isolates, 88.46% (46/52) were rapidly growing mycobacteria (RGM). The predominant NTM species were Mycolicibacterium. sp (23.07%, 12/52) and M. elephantis (15.38%, 8/52), followed by Mycobacteroides chelonae (9.61%, 5/52). At least, two suspected new species were identified. Two core virulence genes were identified in more than 95% of the isolates. Antimicrobial susceptibility testing revealed high resistance among RGM isolates to imipenem (73.91%), while remained sensitive to amikacin and ciprofloxacin. All slowly growing mycobacteria isolates exhibited the highest resistance rate against doxycycline (83.3%, 5/6), but most strains were sensitive to clarithromycin, rifabutin, amikacin, ciprofloxacin, moxifloxacin, rifampin, and trimethoprim-sulfamethoxazole. The prevalence of NTM isolates in Kashgar presents a very specific features and some rarely reported species constitute big proportions. Amikacin and moxifloxacin may represent effective therapeutic options for NTM infections in Kashgar.

Indexed as

Anti-Bacterial AgentsMycobacterium Infections, NontuberculousNontuberculous MycobacteriaChinaDrug Resistance, BacterialFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedVirulence FactorsWhole Genome SequencingAnti-Bacterial AgentsVirulence Factors

Identifiers

PMID40643789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.